Nuvation Bio Inc., a global commercial-stage oncology company, has released a corporate presentation outlining its recent developments and financial status. The presentation highlights the approval of IBTROZI (taletrectinib), a next-generation ROS1 inhibitor, for advanced ROS1+ non-small cell lung cancer (NSCLC) in both the U.S. and China. The company also detailed the progression of Safusidenib, a brain-penetrant mIDH1 inhibitor, which is entering pivotal studies for diffuse IDH1-mutant glioma. Additionally, NUV-1511, Nuvation Bio's first clinical-stage drug-drug conjugate, is undergoing a Phase 1/2 study, while NUV-868, a BD2-selective BET inhibitor, has completed Phase 1 and Phase 1b studies. As of June 30, 2025, Nuvation Bio reports a robust cash balance of $608 million, inclusive of $200 million of non-dilutive capital. You can access the full presentation through the link below.